Brain Metastasis Development Mechanism in BCBM Patients
Launched by SAMSUNG MEDICAL CENTER · Mar 19, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how breast cancer spreads to the brain and what causes this to happen in patients who already have brain metastasis. Researchers want to learn more about the mechanisms behind this so they can improve treatment options for patients. The study is currently recruiting female patients who have breast cancer and are scheduled for surgery to remove brain metastases. However, patients who have already undergone a specific type of treatment called Gamma Knife surgery are not eligible to participate.
If you join this study, you can expect to be part of a research effort that aims to uncover important information about breast cancer and its spread to the brain. Your participation could help improve future care for other women facing similar challenges. This trial is a crucial step towards better understanding and potentially better treatment for breast cancer patients with brain metastases.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Breast cancer
- • Brain metastasis curative surgery patient
- Exclusion Criteria:
- • Gamma Knife surgery patient
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported